ArticleACS medicinal chemistry letters2019
Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a log
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 53 citations in OpenAlex.
- Enantioselective Access to Trifluoromethylated Spirocyclopropyl Heterocycles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- General Synthesis and Properties of Bridged, Fused, and Spirocyclic Azacycles via Intramolecular C-H Bond Amination.ACS medicinal chemistry letters · 2025Article
- Enzymatic Stereodivergent Synthesis of Azaspiro[2.y]alkanes.Journal of the American Chemical Society · 2025Article
- Short Scalable Route to Bis-morpholine Spiroacetals and Oxazepane Analogues: Useful 3D-Scaffolds for Compound Library Assembly.The Journal of organic chemistry · 2025Article
- Article
- Access to 3-Azetidines via Halogenation of Titanacyclobutanes.Advanced synthesis & catalysis · 2024Article
- Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.ACS medicinal chemistry letters · 2024Article
- Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.ACS medicinal chemistry letters · 2024Article
- Silver(I)-Catalyzed Synthesis of Cuneanes from Cubanes and their Investigation as Isosteres.Journal of the American Chemical Society · 2023Article
- Unexplored Facet of Pincer Ligands: Super-Reductant Behavior Applied to Transition-Metal-Free Catalysis.JACS Au · 2023Article
- Turning the Other Cheek: Influence of theACS medicinal chemistry letters · 2022Article
- TheACS medicinal chemistry letters · 2022Article
- A stereochemical journey around spirocyclic glutamic acid analogs.Organic & biomolecular chemistry · 2022Article
- Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.Journal of medicinal chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have conducted an analysis of azaspiro[3.3]heptanes used as replacements for morpholines, piperidines, and piperazines in a medicinal chemistry context. In most cases, introducing a spirocyclic center lowered the measured log
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.